Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Pacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...